A0A2I2YDK8 (A0A2I2YDK8_GORGO) Gorilla gorilla gorilla (Western lowland gorilla)
Bromodomain-containing protein 2 UniProtKBInterProInteractive Modelling
801 aa; Sequence (Fasta) ;
1 identical sequence: Homo sapiens: P25440
It is possible new templates exist for this target since these models were created.
Available Structures
162 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| BRD2-BD1 in complex with cyclic peptide 2.2B |
Heteromer P25440; | 100 | 3×GOL; | |||
| Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated hi… |
Heteromer P02309; P25440; | 100 | ||||
| Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated hi… |
Heteromer P02309; P25440; | 100 | ||||
| Solution structures of Brd2 second bromodomain in complex with stat3 peptide |
Heteromer P25440; P40763; | 100 | ||||
| Structure of human BRD2-BD1 bound to a histone H4 acetyl-methyllysine peptide |
Heteromer P25440; P62805; | 100 | ||||
| Crystal structure of the human Brd2 second bromodomain in complexed with the acetylated histone H4 … |
Heteromer P02309; P25440; | 100 | ||||
| Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13120 | homo-6-mer | 100 | 6×JGR; 2×EDO; 2×PEG; | |||
| Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13157 | homo-4-mer | 100 | 4×JFL; 6×GOL; 15×FMT; | |||
| Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13153 | homo-4-mer | 100 | 4×JFR; 1×DMS; 3×PEG; 4×GOL; | |||
| Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor 22 | homo-4-mer | 100 | 4×XHN; | |||
| Crystal structure of BRD2(BD1)with ligand ZB-BD-224 bound | homo-3-mer | 100 | 2×HFU; | |||
| N-Terminal Bromodomain of Human BRD2 With IBET-151 | homo-2-mer | 100 | 2×ACT; 2×GOL; 2×1GH; | |||
| Crystal Structure of the human BRD2 BD1 bromodomain in complex with a Tetrahydroquinoline analogue | homo-2-mer | 100 | 2×G7V; 1×SO4; 3×EDO; 1×03S; | |||
| N-Terminal bromodomain of Human BRD2 with a Tetrahydroquinoline analogue | homo-2-mer | 100 | 1×SO4; 2×G3J; 1×EPE; | |||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5 ethyl-3-methyl-4-phenyl-1, 2-oxazole | homo-2-mer | 100 | 2×EDO; 2×A9O; 2×SO4; | |||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-cyclopropyl-5-(3,5- dimethyl-1,2-oxazol-4-yl)-2-methylb… | homo-2-mer | 100 | 5×EDO; 2×A9N; 3×SO4; | |||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3-methyl-1,2,3,4- tetrahydroquinazolin-2-one | homo-2-mer | 100 | 2×P9I; 2×SO4; 1×EDO; | |||
| Crystal structure analysis of the N-terminal bromodomain of human Brd2 | homo-2-mer | 100 | 2×DTT; | |||
| N-Terminal Bromodomain of Human BRD2 With tbutyl-phenyl-amino- dimethyl-oxazolyl-quinoline-carboxyl… | homo-2-mer | 100 | 1×EDO; 2×S5B; 2×SO4; | |||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3-methyl-1,2,3,4- tetrahydroquinazolin-2-one | homo-2-mer | 100 | 2×3PF; 4×EDO; 2×SO4; | |||
| BRD2_Bromodomain1 complex with inhibitor 744 | homo-2-mer | 100 | 2×EDO; 2×HWV; | |||
| Crystal Structure of the First Bromodomain of Human Brd2 with the inhibitor GSK525762 (IBET) | homo-2-mer | 100 | 2×EAM; | |||
| Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated hi… | homo-2-mer | 100 | ||||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-cyclopentyl-5-(3,5- dimethyl-1,2-oxazol-4-yl)-2-methylb… | homo-2-mer | 100 | 2×P9M; 2×SO4; | |||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5-(4-(4-fluorophenyl)-1H-imidazol-5-yl)-1-methylpyridin-2… | homo-2-mer | 100 | 2×SO4; 2×NUQ; 1×EDO; | |||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 5-(1-(1,3-dimethoxypropan-2-yl)-5-morpholino-1H-benzo[d]i… | homo-2-mer | 100 | 2×SO4; 2×NUH; 3×EDO; | |||
| Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13142 | homo-2-mer | 100 | 2×JGL; 5×EDO; 1×K; | |||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one | homo-2-mer | 100 | 2×EDO; 2×TVP; 1×SO4; | |||
| crystal structure of BRD2-BD1 in complex with guanosine analog | homo-2-mer | 100 | 2×AC2; 1×DTT; | |||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-METHYLPYRROLIDIN-2-ONE | homo-2-mer | 100 | 2×MB3; 2×SO4; 1×EDO; | |||
| Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13158 | homo-2-mer | 100 | 2×JGU; 4×EDO; 1×PEG; | |||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3,5 dimethyl-4-phenyl-1,2- oxazole | homo-2-mer | 100 | 2×EDO; 2×A9P; 3×SO4; | |||
| crystal structure of BRD2-BD1 in complex with purine derivative | homo-2-mer | 100 | 3×7UH; 2×SO4; | |||
| crystal structure of BRD2-BD1 in complex with purine derivative | homo-2-mer | 100 | 3×37T; 4×SO4; | |||
| Crystal structure of BRD2(BD2) mutant W370F in the free form | homo-2-mer | 99.07 | 2×NI; 2×2PE; 2×GOL; | |||
| Discovery and the crystal structure of NS5 in complex with the N-terminal bromodomain of BRD2. | homo-2-mer | 100 | 1×BUX; 1×SO4; 1×DTT; 1×GOL; 1×DMS; 1×PGE; | |||
| Crystal structure of BRD2(BD1)with ligand BY27 bound | homo-2-mer | 100 | 2×CQF; 1×MES; | |||
| Crystal structure of pyrano 1,3, oxazine derivative in complex with the second bromodomain of BRD2 | homo-2-mer | 100 | 2×PGE; 2×BUX; | |||
| crystal structure of NS5 in complex with the N-terminal bromodomain of BRD2 (BRD2-BD1). | homo-2-mer | 100 | 1×BUX; 1×SO4; | |||
| crystal structure of BRD2-BD1 in complex with purine derivative | homo-2-mer | 100 | 3×TEP; 1×SO4; | |||
| crystal structure of BRD2-BD1 in complex with purine derivative | homo-2-mer | 100 | 2×7UM; 1×EPE; 1×SO4; | |||
| crystal structure of BRD2-BD2 in complex with purine derivative | homo-2-mer | 100 | 4×TEP; | |||
| crystal structure of BRD2-BD2 in complex with purine derivative | homo-2-mer | 99.06 | 2×7UM; 2×GOL; | |||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-(4-hydroxyphenyl) acetamide | homo-2-mer | 100 | 2×EDO; 2×TYL; 4×SO4; | |||
| Crystal Structure of the First Bromodomain of Human Brd2 with the inhibitor GW841819X | homo-2-mer | 100 | 2×WSH; 2×SO4; | |||
| BRD2-BD2 in complex with the cyclic peptide 4.2_3 | homo-2-mer | 100 | ||||
| Solution structure of the Extraterminal (ET) Domain of BRD2 | monomer | 100 | ||||
| BRD2-BD1 in complex with the cyclic peptide 3.2_2 | monomer | 100 | 6×IOD; 2×GOL; 1×NH2; 1×PE3; | |||
| BRD2-BD1 in complex with the cyclic peptide 4.2_3 | monomer | 100 | ||||
| Crystal structure of the N-terminus D161Y bromodomain mutant of human BRD2 | monomer | 99.17 | 5×EDO; 1×ACT; | |||
| Crystal structure of the first bromodomain (BD1) of human BRD2 bound to volasertib | monomer | 100 | 1×IBI; | |||
| N-Terminal bromodomain of Human BRD2 with I-BET726 (GSK1324726A) | monomer | 99.16 | 1×EDO; 1×73B; 1×SO4; | |||
| BRD2-BD1 in complex with the cyclic peptide 3.1_3 | monomer | 100 | 2×ZN; | |||
| CRYSTAL STRUCTURE OF THE HUMAN BRD2 BD1 BROMODOMAIN IN COMPLEX WITH 9-(cyclopropylmethyl)-7-[(2R,6S… | monomer | 100 | 1×YW1; 6×EDO; | |||
| Crystal structure of the N-terminus Y153H bromodomain mutant of human BRD2 | monomer | 99.14 | 3×EDO; | |||
| N-terminal bromodomain of human BRD2 in complex with 4,4'-(quinoline-5,7-diyl)bis(3,5-dimethylisoxa… | monomer | 100 | 2×JWD; | |||
| N-terminal bromodomain of human BRD2 in complex with N-cyclopentyl-7-(3,5-dimethylisoxazol-4-yl)qui… | monomer | 100 | 2×JVY; | |||
| N-terminal bromodomain of human BRD2 with N-((4-(3-(N-cyclopentylsulfamoyl)-4-methylphenyl)-3-methy… | monomer | 100 | 1×JWA; | |||
| Crystal structure of the human BRD2 BD1 bromodomain in complex with a BRD2-interactive compound, BI… | monomer | 100 | 1×BYH; 1×MES; | |||
| X-ray crystal structure of bromodomain 2 of human brd2 in complex with rvx208 to 1.08 A resolution | monomer | 100 | 1×1K0; 1×EDO; | |||
| Human Brd2(BD2) mutant in free form | monomer | 99.11 | 1×9JB; 1×CL; 1×DQW; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (R)-N5-cyclopropyl-N3-methyl-2-oxo-1-(1-phenylethyl)-1,2-… | monomer | 100.0 | 3×EDO; 1×ULH; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH oxabicyclo(hexan-6-yl)-N2-methyl-6-((S)-1-phenylethyl)pyr… | monomer | 100 | 3×EDO; 1×PE4; 1×ULN; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N5-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-3-(1H-indol… | monomer | 100 | 2×EDO; 1×V9Q; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1,5-dimethyl-N-(2-(methylamino)-2-oxo-1-(tetrahydro-2H-py… | monomer | 100 | 1×80Z; 3×EDO; 1×PE4; | |||
| Crystal structure of BRD2(BD2) mutant in free form | monomer | 99.11 | 1×ACT; 1×GOL; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH GSK973 | monomer | 100 | 3×EDO; 1×1PG; 1×QC8; | |||
| Human BRD2 C-terminal bromodomain with (S)-1-(2-cyclopropyl-4-(2-(hydroxymethyl)benzyl)-6-(1,2,3,6-… | monomer | 100 | 2×EDO; 1×D7B; 2×PEG; 1×MES; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH GSK620 | monomer | 100 | 2×EDO; 1×QCZ; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3-(2-(benzyloxy)phenyl)-5-methyl-1H-1,2,4-triazole | monomer | 100 | 3×EDO; 1×PE4; 1×ULB; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 6-((S)-hydroxy(phenyl)methyl)-N2-methyl-N4-((1S,2S)-2-met… | monomer | 100 | 3×EDO; 1×ULK; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1,5-dimethyl-N-(2-(methylamino)-2-oxoethyl)-6-oxo-N-(2-ph… | monomer | 100 | 3×EDO; 1×PE4; 1×VBE; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5-(1-benzyl-4-chloro-1H-imidazol-2-yl)-1,3-dimethylpyridi… | monomer | 100 | 2×EDO; 1×PE4; 1×A1IBV; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N4-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-6-((S)-meth… | monomer | 100 | 3×EDO; 1×ULQ; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (R)-7-((R)-1,2-dihydroxyethyl)-1,3-dimethyl-5-(1-methyl-1… | monomer | 100 | 2×EDO; 1×7PE; 1×P4X; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 7,8-dimethoxy-1,3-dimethyl-1,3-dihydro-2H-benzo[d]azepin-… | monomer | 100 | 3×EDO; 1×PE4; 1×P3R; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH iBET-BD2 (GSK046) | monomer | 100 | 2×EDO; 1×LW5; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 7,8-dimethoxy-1,3-dimethyl-1,3-dihydro-2H-benzo[d]azepin-… | monomer | 100 | 4×EDO; 1×PE4; 1×P0U; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-(2-(1H-imidazol-4-yl)ethyl)-4-acetamido-3-(benzyloxy)be… | monomer | 100 | 2×PEG; 2×EDO; 1×QB5; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-benzyl-N-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide | monomer | 100 | 1×EDO; 1×QCW; 1×MES; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1,3-dimethyl-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-b… | monomer | 100 | 1×NUB; 1×MES; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-methyl-4-propionyl-1H-pyrrole-2-carboxamide | monomer | 100 | 4×EDO; 1×PE4; 1×V9B; | |||
| Human BRD2 C-terminal bromodomain with (S)-5-(1-acetyl-2-cyclopropyl-4-(2-(hydroxymethyl)benzyl)-1,… | monomer | 100 | 1×EDO; 1×MES; 1×D7H; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (S)-N-ethyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)-4-(1-pheny… | monomer | 100 | 3×EDO; 1×UL8; | |||
| Crystal structure of BRD2(BD2) mutant with ligand ET bound (METHYL (2R)- 2-[(4S)-6-(4-CHLOROPHENYL)… | monomer | 99.11 | 1×GOL; 1×2PE; 1×31P; 1×NI; | |||
| Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13146 | monomer | 100 | 1×JGF; 1×EDO; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-ethyl-2-(1-methyl-1H-1,2,3-triazol-4-yl)-6-(1-phenyleth… | monomer | 100 | 1×UME; 3×EDO; 1×PEG; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (S)-N4-cyclopropyl-N2-methyl-6-(1-phenylethyl)pyridine-2,… | monomer | 100 | 1×ULE; 2×EDO; | |||
| Human Brd2(BD2) mutant in complex with ME | monomer | 99.11 | 1×31O; 1×CL; 1×DQW; | |||
| Human BRD2 C-terminal bromodomain with 2-((4-acetyl-3-cyclopropyl-3,4-dihydroquinoxalin-1(2H)-yl)me… | monomer | 100 | 2×PEG; 2×EDO; 1×D7Q; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5-(1-(1,3-dimethoxypropan-2-yl)-5-morpholino-1H-benzo[d]i… | monomer | 100 | 3×EDO; 1×PE4; 1×NV2; | |||
| Crystal structure of the second bromodomain (BD2) of human BRD2 bound to LRRK2-IN-1 | monomer | 100 | 1×BU1; 2×4K4; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH GSK549 | monomer | 100 | 3×EDO; 1×QD5; 1×PEG; | |||
| Human Brd2(BD2) mutant in complex with AL-tBu | monomer | 99.1 | 1×9HN; 1×CL; 1×DQW; | |||
| Crystal structure of the BRD2-BD2 in complex with a ligand | monomer | 100 | 1×EDO; 1×QJ1; | |||
| X-ray crystal structure of human BRD2(BD2) in complex with RVX297 to 1.55 A resolution | monomer | 100 | 1×5GD; | |||
| Human Brd2(BD2) mutant in complex with 9-Me | monomer | 99.1 | 1×9J2; 1×CL; 1×DQW; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 6-benzyl-N2-methyl-N4-((1S,2S)-2-methylcyclopropyl)pyridi… | monomer | 100 | 1×UL5; 3×EDO; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-benzyl-N5-cyclopropyl-N3-methyl-1H-pyrazole-3,5-dicarbo… | monomer | 100 | 4×EDO; 1×VE5; 1×PEG; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-ethyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)-4-(pyridin-2-y… | monomer | 100 | 3×EDO; 1×UM5; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 2-benzyl-N-cyclopropyl-6-(1-methyl-1H-1,2,3-triazol-4-yl)… | monomer | 100 | 1×UM8; 3×EDO; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 7,8-dimethoxy-3-methyl-1,3-dihydro-2H-benzo[d]azepin-2-one | monomer | 100 | 2×EDO; 1×P4M; 1×MES; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N4-hydroxycyclohexyl-N2-methyl-5-phenylethyl-furan-2,4-di… | monomer | 100 | 1×V9K; 2×EDO; | |||
| BRD2-BD1 in complex with MDP5 | monomer | 100 | 1×O6O; 4×PEG; 5×EDO; 1×DMS; 1×CL; 1×NA; | |||
| Crystal structure of the second bromodomain (BD2) of human BRD2 bound to BI2536 | monomer | 100 | 2×EDO; 1×R78; 1×CL; | |||
| Crystal structure of BRD2 second bromodomain in complex with SGC-CBP30 chemical probe | monomer | 100 | 4×EDO; 1×2LO; | |||
| Crystal structure of the second bromodomain (BD2) of human BRD2 bound to bromosporine | monomer | 100 | 1×BMF; 8×EDO; 1×SO4; | |||
| Human Brd2(BD2) L383V mutant in complex with ET-JQ1-OMe | monomer | 99.09 | 1×PMW; 2×PXN; | |||
| Human Brd2(BD2) mutant in complex with 9-ET | monomer | 99.09 | 1×9J5; 1×CL; 1×DQW; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH iBET-BD1 (GSK778) | monomer | 100 | 1×LWB; 2×EDO; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N5-hydroxycyclohexyl-N3-methyl-1-phenylethyl-1H-pyrazole-… | monomer | 100 | 1×V9H; 2×EDO; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-(2,2-diphenylethyl)-1,5-dimethyl-N-(2-(methylamino)-2-o… | monomer | 100 | 1×VBH; 1×EDO; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 2-benzyl-N-cyclopropyl-6-(1-methyl-1H-1,2,3-triazol-4-yl)… | monomer | 100 | 1×UMB; 5×EDO; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH rac-N5-((1R,5S)-3-oxabicyclo[3.1.0]hexan-6-yl)-N7,3-dimet… | monomer | 100 | 1×V9N; 2×EDO; | |||
| C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (S)-5-(1-((1-acetylpiperidin-3-yl)methyl)-5-bromo-1H-benz… | monomer | 100 | 1×EDO; 1×MES; 1×I0U; | |||
| Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor JQ1 | monomer | 100 | 1×JQ1; 2×NI; 2×EDO; | |||
| Crystal Structure of the second bromodomain of human BRD2 in complex with a quinazolinone ligand (R… | monomer | 100 | 4×EDO; 1×DMS; 1×1K0; | |||
| Crystal Structure of the second bromodomain of human BRD2 in complex with a quinazolinone ligand (R… | monomer | 100 | 3×EDO; 1×DMS; 1×1K0; | |||
| Human Brd2(BD2) mutant in complex with ET-Am1 | monomer | 99.09 | 1×9HT; 1×CL; 1×DQW; | |||
| Crystal structure of BRD2(BD2) mutant with ligand ME bound (METHYL (2R)- 2-[(4S)-6-(4-CHLOROPHENYL)… | monomer | 99.09 | 1×31O; 1×2PE; 1×NI; 1×GOL; | |||
| Human Brd2(BD2) mutant in complex with AL-Am1 | monomer | 99.09 | 1×9J8; | |||
| Crystal structure of the second bromodomain (BD2) of human BRD2 bound to Ro3280 | monomer | 100 | 1×79C; 1×CL; | |||
| C-terminal bromodomain of human BRD2 in complex with 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1H-… | monomer | 100 | 1×JW4; 1×GOL; | |||
| Human Brd2(BD2) mutant in complex with 9-ME-Am1 | monomer | 99.08 | 1×9HQ; 1×CL; 1×DQW; | |||
| Human Brd2(BD2) mutant in complex with Me-Am1 | monomer | 99.08 | 1×9HW; 1×CL; 1×DQW; | |||
| Crystal structure of the second bromodomain Q443H mutant of human BRD2 | monomer | 99.08 | ||||
| BRD2-BD2 in complex with the cyclic peptide 3.1_3 | monomer | 100 | ||||
| Crystal structure of BRD2(BD2) W370F mutant with ligand I-BET 762 bound | monomer | 99.08 | 1×GOL; 1×2PE; 1×EAM; 1×NI; | |||
| Bromodomain-containing 2 BD2 in complex with the inhibitor CRCM5484 | monomer | 100 | 1×8M6; 3×EDO; | |||
| Peptide 2.2E in complex with BRD2-BD2 | monomer | 100 | 1×ACE; 1×NH2; | |||
| N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-((2R,4S)-2-methyl-4-(phenylamino)-6-(4-(piperidin-1-ylm… | monomer | 100 | 1×9S3; | |||
| BRD2-BD2 in complex with a diacetylated-H2A.Z peptide | monomer | 100 | ||||
| X-ray crystal structure of 1,2,3-triazolobenzodiazepine in complex with BRD2(D2) | monomer | 100 | 1×7WY; 5×EDO; | |||
| Crystal structure of the N-terminus R100L bromodomain mutant of human BRD2 | monomer | 99.08 | 1×EDO; | |||
| Crystal structure of the second bromodomain of human BRD2 in complex with a tetrahydroquinoline ana… | monomer | 100 | 1×SO4; 2×EDO; 1×8J2; | |||
| C-Terminal bromodomain of Human BRD2 with I-BET726 (GSK1324726A) | monomer | 100 | 1×73B; 2×SO4; | |||
| Ultra high resolution crystal structure of the apo- form of second bromodomain of BRD2. | monomer | 100 | 1×CL; 5×GOL; 2×PGE; | |||
| Second bromodomain of Human BRD2 with a Tetrahydroquinoline analogue | monomer | 100 | 7×EDO; 1×G3J; | |||
| Crystal Structure of the human BRD2 BD2 bromodimain in complex with a Tetrahydroquinoline analogue | monomer | 100 | 1×G7V; 5×EDO; | |||
| Crystal Structure of the second bromodomain of BRD2 in complex with RT53 | monomer | 100 | 1×H7B; 1×EDO; | |||
| BRD2-BD2 in complex with MDP5 | monomer | 100 | 1×O6O; 2×EDO; 1×NA; | |||
| Crystal structure of BRD2(BD2)with ligand BY27 bound | monomer | 100 | 1×CQF; | |||
| BRD2-BD2 in complex with SF2523 | monomer | 100 | 1×82V; 5×EDO; | |||
| Crystal structure of the BRD2-BD2 in complex with phenanthridinone | monomer | 100 | 2×GOL; 1×2ME; 1×LDR; | |||
| Crystal Structure of the second bromodomain of human BRD2 in complex with the compound 3b | monomer | 100 | 3×EDO; 1×YA3; | |||
| Crystal structure analysis of the second bromodomain of BRD2 covalently linked to b-mercaptoethanol | monomer | 100 | 1×PGE; 3×GOL; | |||
| Crystal structure of BRD2(BD2) W370F mutant with ligand 28 bound | monomer | 99.07 | 1×59E; 1×GOL; | |||
| Crystal structure of Phenanthredinone moiety in complex with the second bromodomain of BRD2 (BRD2-B… | monomer | 100 | 1×LDR; 1×PGE; | |||
| Crystal Structure of the second bromodomain of BRD2 in complex with RT56 | monomer | 100 | 1×MES; 1×EDO; 1×H7E; | |||
| Crystal structure of the second bromodomain of the human Brd2 protein | monomer | 100 | 1×EPE; | |||
| BRD2 Bromodomain2 with A-1360579 | monomer | 100 | 1×87D; | |||
| Human Brd2(BD2) mutant in complex with AL | monomer | 99.07 | 1×9HZ; | |||
| Crystal Structure of BRD2(BD2)with Ligand ZB-BD-224 bound | monomer | 100.0 | 1×HFU; | |||
| Human Brd2(BD2) mutant in complex with ET | monomer | 99.07 | 1×31P; | |||
| Solution structure of a Bromodomain from RING3 protein | monomer | 99.07 | ||||
| Ultra-high resolution crystal structure of second bromodomain of BRD2 in complex with inhibitor 6B3 | monomer | 100 | 2×CL; 2×GOL; 1×6B3; | |||
| crystal structure of BRD2-BD2 in complex with purine derivative | monomer | 99.06 | 1×37T; 1×GOL; | |||
| crystal structure of BRD2-BD2 in complex with purine derivative | monomer | 100 | 2×7UH; 1×GOL; | |||
| crystal structure of BRD2-BD2 in complex with guanosine analog | monomer | 98.13 | 1×AC2; | |||
| BRD2_Bromodomain2 complex with pyrrolopyridone compound 27 | monomer | 100 | 1×QYY; | |||
| Crystal structure of the second bromodomain of human BRD2 in complex with a tetrahydroquinoline inh… | monomer | 100 | 1×5P4; | |||
| BRD2_Bromodomain2 complex with inhibitor 744 | monomer | 100 | 1×HWV; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8ov6.1.C | monomer | 0.55 | 62.92 | |||